Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

Recruiting now

Conditions studied: Chronic Lymphocytic Leukemia

In brief

to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL

Key facts

Study ID

NCT07288515

Run by

AstraZeneca

People needed

50

Starts

2025-12-31

Expected to finish

2029-12-31

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years.
• Confirmed diagnosis of CLL.
• Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.
• Treatment-naïve or R/R CLL.
• Ability and willingness to provide informed consent for study participation.

You may not qualify if…

• Patients not satisfying any of the inclusion criteria.
• Prior treatment with any BTK inhibitor.
• Participation in other ongoing clinical trials.
• Pregnant or breastfeeding females

Where it is running

• Research Site — Minsk, Belarus (enrolling)
• Research Site — Grodno, Belarus
• Research Site — Homyel, Belarus

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.